Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Envarsus XR + azathioprine
- Development stage
- Unknown
- Lead developer
- Veloxis Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Envarsus XR + azathioprine is a once-daily immunosuppressive regimen being evaluated by the Washington University School of Medicine for use in kidney transplant recipients. This combination consists of Envarsus XR, an extended-release formulation of the calcineurin inhibitor tacrolimus, and azathioprine, a purine synthesis inhibitor. The regimen is designed to improve patient compliance and tolerability compared to standard twice-daily regimens (such as immediate-release tacrolimus combined with mycophenolic acid) while maintaining efficacy in preventing biopsy-proven organ rejection. Envarsus XR utilizes MeltDose technology to enhance bioavailability and allow for once-daily dosing with a smoother pharmacokinetic profile and reduced peak-to-trough fluctuations compared to immediate-release tacrolimus formulations.
- Other names
- LCP-tacrolimus + azathioprineLCPT + azathioprineOnce-daily tacrolimus + azathioprineextended-release tacrolimus + azathioprine
02
Targets
CN (Calcineurin)RAC1 (Rac family small GTPase 1)PPAT (Amidophosphoribosyltransferase)DNA
Beyond the preview
Go deeper on Envarsus XR + azathioprine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Envarsus XR + azathioprine.